Alpha Cognition Appoints Caren Deardorf to Board of Directors to Support ZUNVEYL Commercial Launch and Pipeline Development
Alpha Cognition Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for debilitating neurodegenerative disorders, has announced the appointment of experienced pharmaceutical and biotechnology executive Caren Deardorf to its Board of Directors. The appointment became effective November 9, 2026, as the company continues to advance its commercial and clinical development priorities.
Deardorf brings decades of experience across the pharmaceutical and biotechnology sectors, with expertise spanning commercial strategy, product development, brand management, product launches, business development and corporate strategy. Her background includes leadership positions at established biopharmaceutical companies and emerging biotechnology organizations, where she has helped guide products from research and development through commercialization.
Alpha Cognition expects her industry experience to contribute to the company’s strategic direction as it works to expand the commercial launch of ZUNVEYL® and advance its sublingual development program. The appointment comes at an important stage for the company as it focuses on building its commercial capabilities while continuing to develop treatments for patients affected by neurodegenerative conditions.
Michael McFadden, chief executive officer of Alpha Cognition, welcomed Deardorf to the Board on behalf of the company.
“On behalf of the entire Board of Directors, it is a pleasure to welcome Caren Deardorf,” McFadden said. “Caren is a highly accomplished industry leader. Her broad experience across strategic, commercial, and operational roles will be instrumental as we advance the commercial launch of ZUNVEYL® and continue development of our sublingual program. We look forward to benefiting from her insight and leadership.”
Deardorf also expressed enthusiasm about joining the company’s Board at this stage of its development. She highlighted the potential of ZUNVEYL to make a meaningful difference for individuals living with Alzheimer’s disease and their families.
“I’m excited to join Alpha Cognition’s Board at such an important time for the Company,” Deardorf said. “ZUNVEYL® has the potential to make a meaningful difference for people living with Alzheimer’s disease and their families, and I look forward to working with Michael and the Board as the Company builds on its commercial launch and pursues its broader pipeline.”
Extensive Leadership Experience Across Biotechnology and Pharmaceuticals
Deardorf currently serves as chief business and strategy officer at Neutrolis, Inc., a privately held, clinical-stage biotechnology company developing therapies for autoimmune diseases. In this role, she leads the organization’s commercial and corporate strategy, including business development, investor relations and program leadership.
Her responsibilities at Neutrolis involve supporting the company’s broader business priorities and helping align its development programs with commercial and strategic objectives. Her experience in this position adds to a career that has included leadership across a range of biotechnology organizations at different stages of growth.
Before joining Neutrolis, Deardorf served as chief commercial and strategy officer at Editas Medicine. During her tenure, she oversaw commercial and portfolio strategy, contributing to the company’s efforts to align its development pipeline and business priorities with its long-term objectives.
Editas Medicine is a biotechnology company focused on developing medicines using gene-editing technologies. Deardorf’s role involved applying her commercial and strategic experience within an innovative biotechnology environment, where companies must consider clinical development, market opportunities, portfolio priorities and future commercialization requirements.
Earlier, she held the position of chief commercial officer at Magenta Therapeutics and Ohana Biosciences. At both companies, she helped support the transition from research-focused operations toward development and commercialization. Her work included scaling organizational operations, strengthening commercial readiness and establishing value-based approaches to portfolio prioritization.
These positions provided Deardorf with experience in building commercial capabilities within emerging biotechnology companies. Such experience can be particularly important for organizations advancing novel therapies, as they prepare for later-stage development, potential regulatory milestones and eventual market introduction.
Across these leadership roles, Deardorf has worked at the intersection of commercial planning, corporate strategy and product development. Her experience includes helping companies assess development opportunities, establish priorities, build operational capabilities and prepare for the commercial requirements associated with bringing new therapies to patients.
Two Decades at Biogen and Leadership of the SPINRAZA Launch
A significant part of Deardorf’s professional background comes from her 20-year career at Biogen, where she held positions of increasing responsibility across U.S. and global commercial operations and product development.
Her career at Biogen culminated in the role of vice president, global product development and commercialization lead for SPINRAZA® and the company’s spinal muscular atrophy (SMA) portfolio. In this position, she played a leading role in the launch and commercialization of SPINRAZA, which became the first approved treatment for SMA.
The introduction of SPINRAZA represented an important development for the SMA treatment landscape. Before the availability of approved disease-modifying therapies, treatment options for people living with SMA were limited, and the condition presented significant challenges for patients, caregivers and healthcare professionals.
Deardorf’s leadership in the SPINRAZA launch involved coordinating commercial and product development activities across markets. The product generated approximately $2 billion in revenue during its first two years, while securing reimbursement in approximately 30 countries.
The launch demonstrated the importance of combining commercial execution with market access planning and coordinated global operations. Securing reimbursement across multiple countries requires engagement with healthcare systems and payers, as well as an understanding of regional treatment pathways and the value proposition of a new medicine.
Her experience with SPINRAZA also gave her exposure to the challenges associated with introducing a first-in-class treatment for a serious rare disease. Such launches require organizations to build awareness among healthcare professionals, support patient access and establish commercial infrastructure while addressing the needs of a relatively specialized patient population.
In addition to her work on the SMA portfolio, Deardorf played an important role in Biogen’s development as a leader in multiple sclerosis (MS). During her tenure, she contributed to a series of first-in-class and best-in-class product launches in a highly competitive market.
Multiple sclerosis is a chronic neurological condition requiring long-term disease management. The treatment landscape has evolved considerably through the introduction of disease-modifying therapies, with competition among pharmaceutical companies driving continued innovation and the development of new treatment options.
Deardorf’s experience across the MS portfolio involved navigating a competitive commercial environment and supporting product strategies designed to strengthen Biogen’s position in the market. Her work across both multiple sclerosis and SMA provided experience in commercializing therapies for complex neurological conditions, including products that address significant unmet medical needs.
This background is particularly relevant to Alpha Cognition, which is focused on therapies for neurodegenerative disorders. Her experience with neurological products, global commercialization and market access may provide strategic insight as the company works to establish and expand its commercial presence.
Board Experience and Contributions Beyond the Biopharmaceutical Industry
In addition to her executive leadership experience, Deardorf has served in corporate governance and nonprofit leadership roles.
She recently served on the board of directors of Crinetics Pharmaceuticals from March 2022 until the company’s acquisition by Vertex Pharmaceuticals. Her involvement provided additional experience in board-level oversight and strategic decision-making within the biotechnology sector.
Board responsibilities at biotechnology companies can include evaluating corporate strategy, reviewing development priorities, overseeing management performance and considering opportunities that may influence long-term shareholder value. Deardorf’s experience at Crinetics adds a governance dimension to her background beyond her operational and commercial leadership positions.
She is also a member of the board of directors of the Pan-Massachusetts Challenge, a nonprofit organization that has raised more than $1.2 billion for the Dana-Farber Cancer Institute through its annual cycling event.
The Pan-Massachusetts Challenge brings together participants, volunteers and supporters to raise funds for cancer research and related initiatives. Its annual bike ride has become a major fundraising activity, with proceeds supporting the work of Dana-Farber Cancer Institute.
Deardorf’s involvement with the organization reflects an additional commitment to healthcare-related initiatives outside the commercial biotechnology sector. Her nonprofit board experience complements her corporate governance background and broadens the perspective she brings to Alpha Cognition’s Board.
Supporting Alpha Cognition’s Commercial and Development Priorities
Deardorf’s appointment is expected to support Alpha Cognition as it works to advance its commercial strategy for ZUNVEYL and continue development of its broader pipeline.
The company is focused on developing and commercializing treatments for debilitating neurodegenerative disorders, with Alzheimer’s disease representing an important area of its commercial activity. Through ZUNVEYL, Alpha Cognition is seeking to address the needs of individuals living with Alzheimer’s disease and the families and caregivers who support them.
Commercializing a treatment in the Alzheimer’s disease market involves several challenges, including communicating clinical and product information to healthcare professionals, establishing relationships across the healthcare system, supporting patient access and building awareness among relevant stakeholders.
Deardorf’s experience in launching neurological therapies, including SPINRAZA, and her work across global commercial strategy may help the company navigate these requirements. Her background in market access and reimbursement is also relevant as Alpha Cognition seeks to develop its commercial operations and reach appropriate patient populations.
The company’s plans extend beyond its current commercial activities. Alpha Cognition is also continuing development of its sublingual program, which forms part of its broader pipeline strategy. Deardorf’s experience in portfolio management, business development and commercial readiness may contribute to decisions regarding the advancement and prioritization of these development programs.
Her previous roles at emerging biotechnology companies have involved supporting organizations as they move from early research toward clinical development and commercialization. This experience may be valuable to Alpha Cognition as it balances the demands of commercial execution with continued investment in research and development.
Strategic Importance of the Board Appointment
The addition of Deardorf strengthens Alpha Cognition’s Board with an executive who has experience across several stages of the biopharmaceutical business lifecycle. Her career includes leadership in established pharmaceutical organizations, commercial strategy positions at clinical-stage biotechnology companies, product launch management and corporate governance.
Her work at Biogen demonstrates experience with large-scale commercialization and global market access, while her subsequent roles at Editas Medicine, Magenta Therapeutics, Ohana Biosciences and Neutrolis provide exposure to different biotechnology business models and development stages.
For Alpha Cognition, this combination of experience is expected to be relevant as it seeks to build its commercial organization, support the launch of ZUNVEYL and continue developing its pipeline. The appointment also adds a board member with direct experience in neurological disease treatment markets and the commercialization of therapies addressing serious medical conditions.
The company has not announced specific changes to its development strategy or commercial plans in connection with the appointment. However, management expects Deardorf’s strategic, commercial and operational knowledge to contribute to the Board’s oversight and guidance as Alpha Cognition pursues its business objectives.
With her appointment effective November 9, 2026, Deardorf joins the Board at a significant point in the company’s development. Her experience in pharmaceutical launches, portfolio strategy, business development and biotechnology leadership is expected to support Alpha Cognition’s efforts to advance ZUNVEYL’s commercial launch and progress its broader pipeline of potential treatments for neurodegenerative disorders.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients with neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are limited or no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.